various therapies e.g. cancer, inflammatory and autoimmune diseases. Several biosimilar drugs, supposed to be economical version of branded biological drugs, are in the process of drug development for market approval
multiple comorbidities related to insulin resistance and inadequate diabetic control, which predispose to the development of further complications. Currently, drug treatment effects on body weight and cardiovascular…
facilitate this appraisal process. QAS analysis methods have been applied in trials with breast cancer patients of adjuvant therapies as well as treatments for advanced/metastatic disease. QAS analyses based ... explore…
proposed to explain the difference in the age of onset on hypothyroidism and the development of goiter. Significantly, genetic screening is highly recommended in patients with severely reduced radioiodide accumulation…
Background: Rapid changes and development of the health care system evoke the necessitation of professional health caregiver to always be updated. In 2011, the IOM and other nursing institutes performed ... their daily…
association with nonmelanoma skin cancers (NMSC). Current methods for detection of HPV in clinical specimens are molecular based. A variety of molecular techniques developed for diagnosis of HPV; focus more
significant problem in patients with head and neck cancer undergoing chemoradiation treatments. Severe OM develops in more than 90% of patients undergoing combined chemotherapy and radiation. OM is not only
predict clinical outcome. This commentary highlights current benefits and limitations of developing novel mouse models of cancer to subsequently improve clinical trial outcome in humans
small-cell lung cancer represents the leading cause of cancer-related death in the western world. Unfortunately, the majority of patients are diagnosed with advanced, unresectable disease that remains incurable…
Epigenetic modification has recently been recognized as an important factor in the development of therapy resistance in cancer. Hence, histone deacetylase inhibitors as potential epigenetic modifiers are an emerging…
Survival for cancer patients has improved through the identification of potentially effective biologic targets and development of new clinical therapies directed at these targets. Significant advances over the past…
such as immune checkpoint inhibitors and DNA- and peptide-based vaccines are also in development and clinical testing. Based on the logistics of their production, these platforms are broadly categorized ... shelf…
clinical outcomes are hindered by the alternate survival mechanisms either innately active or developed by the cancer cell over time. Identifying these signaling pathways at the outset or over
other chemotherapy agents has been shown to be safe, tolerable and efficacious in prostate cancer. Multiple trials are underway combining various antineoplastic agents with valproic acid in an attempt ... efficacy of…
treatment-related, a co-morbid illness or a combination of all three. Additionally, as cancer progresses, both the symptoms and treatments evolve, resulting in a complex, time-dependent relationship ... result of an…
development of drugs improving overall survival (OS) in late-stage metastatic breast cancer (MBC) remains a challenge. Eribulin mesylate, a new chemotherapy agent, has shown significant results in this setting ... drug…
Drawing on findings from earlier stages in the study, a structured interview schedule was developed to form the basis of focus group discussions. Groups were held across nine countries ... Discussants were those living…
EGFR has become an important target in lung cancer treatment. Reversible inhibitors of this receptor have been shown to improve outcomes for patients whose tumors harbor EGFR mutations, as well ... those with wild-type…
overview of the c-MET signaling pathway, including its role in the development of cancers, and presents data that support this pathway as a relevant target for personalized cancer treatment
important role in many oncologic functions in human cancers, including proliferation, motility, migration, survival and angiogenesis. Several Src inhibitors have been developed, of which dasatinib has been most explored…
vicious cycle of bone resorption and destruction. Exploiting this triad led to the development of denosumab, a fully-human monoclonal antibody to RANKL. The success of this bone-directed agent ... multi-center…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.